TEV-53408

Phase 2Small molecule

Teva

TEV-53408 is one of 68 small molecule programs targeting Celiac Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Celiac DiseaseActive, not recruiting

VitiligoActive, not recruiting

Celiac DiseasePhase 2

Active, not recruiting

VitiligoPhase 1

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Vitiligo

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

3 2

Opzelura

Pfizer

Phase 3

2 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

8 4

Povorcitinib

Incyte

Phase 3

2 5

Olumiant

Eli Lilly

Phase 2

3 6

Otezla

Amgen

Phase 2

2 7

Saphnelo

AstraZeneca

Phase 2

1 8

Scenesse

CClinuvel Pharmaceuticals Limited

Phase 2

4 9

Enbrel

IImmunex

Phase 2

1 10

Glucophage

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Vitiligo

NCT06625177

Q3 2027

Phase 2Active, not recruiting

Celiac Disease

NCT06807463

Clinical

Trials by Indication[1]

Vitiligo1 trial

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Active, not recruiting· Teva logo

Teva·Phase 1·NCT06625177·38 enrolled

Celiac Disease1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure

Active, not recruiting· Teva logo

Teva·Phase 2·NCT06807463·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TEV-53408. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TEV-53408 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TEV-53408. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Teva

TEV-53408

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Vitiligo1 trial

Celiac Disease1 trial

References

Drug Info

Quick Facts

Related News